Contineum Therapeutics

Company snapshot

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Contineum Therapeutics. Not investment advice.

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 40

• Peer + 0 momentum

  Shanghai Zerun Biotechnology

  TA overlap score 22.2

• Peer + 0 momentum

  Trevi Therapeutics

  TA overlap score 22.2

Recent activity

Latest pipeline, patent, and corporate events for Contineum Therapeutics.

1. Jun 5, 2026 Clinical update

   PIPE-791 Dose A — Phase 2

2. Jun 5, 2026 Clinical update

   PIPE-505 — Phase 2

3. Jun 5, 2026 Clinical update

   PIPE-307 Dose A — Phase 2

4. May 23, 2026 Clinical update

   PIPE-307 — Phase 1

5. May 23, 2026 Clinical update

   PIPE-791 — Phase 1

View all clinical trial activity →

• What is Contineum Therapeutics?

  Contineum Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker CTNM. Primary therapeutic focus areas include Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Sensorineural Hearing Loss, Chronic Osteoarthritis Pain, Idiop

• Is Contineum Therapeutics publicly traded?

  Yes. Contineum Therapeutics is listed with ticker CTNM on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Contineum Therapeutics develop or market?

  We link 3 drug profile(s) where Contineum Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/contineum-therapeutics#company-drugs.

• What are the latest developments for Contineum Therapeutics?

  In the last 12 months our linked public records show 7 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Contineum Therapeutics focus on?

  Contineum Therapeutics focuses on Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Sensorineural Hearing Loss based on our analysis of their pipeline programs and drug development activities.